• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Therapeutic drug monitoring of clozapine treatment. Therapeutic threshold value for serum clozapine concentrations.

作者信息

Olesen O V

机构信息

Department of Biological Psychiatry, Psychiatric Hospital, Aarhus University Hospital, Risskov, Denmark.

出版信息

Clin Pharmacokinet. 1998 Jun;34(6):497-502. doi: 10.2165/00003088-199834060-00005.

DOI:10.2165/00003088-199834060-00005
PMID:9646010
Abstract

It has been suggested that the minimum effective serum clozapine concentration for an acceptable clinical response (threshold value) is about 400 micrograms/L. This article argues against the use of therapeutic drug monitoring (TDM) as a tool to obtain clozapine concentrations of > or = 400 micrograms/L in the individual patient from the start of clozapine treatment. The following arguments are presented: (i) because of a great interindividual variability of the clozapine concentration to dose ratio (C/D) it can be calculated that extremely high daily doses (900 to 1800 mg/day) would be necessary in 15% of patients to obtain a clozapine concentration of 400 micrograms/L; (ii) doses of 200 to 300 mg/day are commonly used in Central Europe. although about 80% of the patients can be expected to have clozapine concentration < 400 micrograms/L; (iii) in a double-blind study, no difference in clinical response was found between patients treated with clozapine in the concentration range of 200 to 300 micrograms/L, and a group with higher clozapine concentrations; (iv) positron emission topography (PET) studies indicate that maximum receptor occupancy is obtained at clozapine concentrations of about 200 micrograms/L and no further receptor occupancy is obtained by increasing clozapine concentrations to > or = 400 micrograms/L; (v) the frequency of both severe clozapine-induced adverse effects (seizure and confusion) and more common adverse effects increases with increasing doses/clozapine concentrations. It is concluded that the antipsychotic effects and adverse effects of clozapine occur over a very broad range of serum concentrations. In most countries the majority of patients are treated with clozapine concentrations well below the 400 micrograms/L suggested as threshold concentration for optimum response. Therefore clinical judgement should always be primarily used for dose adjustments. TDM is useful to follow compliance and to adjust for extreme serum concentrations and revealing drug interactions.

摘要

相似文献

1
Therapeutic drug monitoring of clozapine treatment. Therapeutic threshold value for serum clozapine concentrations.
Clin Pharmacokinet. 1998 Jun;34(6):497-502. doi: 10.2165/00003088-199834060-00005.
2
Will routine therapeutic drug monitoring have a place in clozapine therapy?常规治疗药物监测在氯氮平治疗中会占有一席之地吗?
Clin Pharmacokinet. 1997 Feb;32(2):93-100. doi: 10.2165/00003088-199732020-00001.
3
Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.非典型抗精神病药物的临床药代动力学:血浆浓度与临床反应之间关系的批判性综述
Clin Pharmacokinet. 2007;46(5):359-88. doi: 10.2165/00003088-200746050-00001.
4
Therapeutic drug monitoring data: risperidone does not increase serum clozapine concentration.
Eur J Clin Pharmacol. 2002 Dec;58(9):587-91. doi: 10.1007/s00228-002-0523-9. Epub 2002 Nov 13.
5
Cytochrome P450 and therapeutic drug monitoring with respect to clozapine.细胞色素P450与氯氮平的治疗药物监测
Eur Neuropsychopharmacol. 1999 Dec;9(6):453-9. doi: 10.1016/s0924-977x(99)00033-4.
6
Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia.治疗抵抗性精神分裂症患者血清氯氮平水平的临床预测因子。
Int Clin Psychopharmacol. 2013 Jan;28(1):50-6. doi: 10.1097/YIC.0b013e32835ac9da.
7
Prescribing and monitoring clozapine in Christchurch.克赖斯特彻奇市氯氮平的处方开具与监测
Australas Psychiatry. 2008 Aug;16(4):263-7. doi: 10.1080/10398560802189896.
8
Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies.治疗成人精神分裂症的氯氮平的药物监测:挑战与策略的综述。
Expert Opin Drug Metab Toxicol. 2021 Oct;17(10):1211-1221. doi: 10.1080/17425255.2021.1974400. Epub 2021 Sep 6.
9
Using therapeutic drug monitoring to personalize clozapine dosing in Asians.利用治疗药物监测实现亚洲人群氯氮平个体化给药。
Asia Pac Psychiatry. 2020 Jun;12(2):e12384. doi: 10.1111/appy.12384. Epub 2020 Mar 2.
10
Unanticipated plasma concentrations in two clozapine-treated patients.两名接受氯氮平治疗的患者出现意外的血浆浓度。
Ann Pharmacother. 2001 Sep;35(9):1028-31. doi: 10.1345/aph.10227.

引用本文的文献

1
Combining Therapeutic Drug Monitoring and Pharmacokinetic Modelling Deconvolutes Physiological and Environmental Sources of Variability in Clozapine Exposure.结合治疗药物监测与药代动力学建模解析氯氮平暴露中生理和环境变异来源。
Pharmaceutics. 2021 Dec 27;14(1):47. doi: 10.3390/pharmaceutics14010047.
2
A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology.基于药物不良反应、药代动力学和临床精神药理学的氯氮平合理应用。
Psychother Psychosom. 2020;89(4):200-214. doi: 10.1159/000507638. Epub 2020 Apr 14.
3
A Comparative Study of the Pharmacokinetics of Clozapine -Oxide and Clozapine -Oxide Hydrochloride Salt in Rhesus Macaques.

本文引用的文献

1
Will routine therapeutic drug monitoring have a place in clozapine therapy?常规治疗药物监测在氯氮平治疗中会占有一席之地吗?
Clin Pharmacokinet. 1997 Feb;32(2):93-100. doi: 10.2165/00003088-199732020-00001.
2
[Serious drug interaction between clozapine-Leponex and fluvoxamine-Fevarin].
Ugeskr Laeger. 1996 Nov 25;158(48):6931-2.
3
Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges.难治性精神分裂症患者在三个血清水平范围内对氯氮平的反应。
氯氮平氧化物及其盐酸盐在食蟹猴体内药代动力学的比较研究。
J Pharmacol Exp Ther. 2019 Feb;368(2):199-207. doi: 10.1124/jpet.118.252031. Epub 2018 Dec 6.
4
Multidimensional mapping method using an arrayed sensing system for cross-reactivity screening.使用阵列传感系统进行交叉反应性筛选的多维映射方法。
PLoS One. 2015 Mar 19;10(3):e0116310. doi: 10.1371/journal.pone.0116310. eCollection 2015.
5
Role of Statistical Random-Effects Linear Models in Personalized Medicine.统计随机效应线性模型在个性化医疗中的作用。
Curr Pharmacogenomics Person Med. 2012 Mar;10(1):22-32. doi: 10.2174/1875692111201010022.
6
Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?氯氮平与治疗药物监测:是否有足够的证据设定上限?
Psychopharmacology (Berl). 2013 Feb;225(3):505-18. doi: 10.1007/s00213-012-2922-7. Epub 2012 Nov 22.
7
What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia.使用氯氮平的充分试验是什么?:难治性精神分裂症的治疗药物监测及起效时间
Clin Pharmacokinet. 2003;42(7):607-18. doi: 10.2165/00003088-200342070-00001.
8
Atypical neuroleptics in child and adolescent psychiatry.儿童及青少年精神病学中的非典型抗精神病药物。
Eur Child Adolesc Psychiatry. 2000;9 Suppl 1:I9-19. doi: 10.1007/s007870070015.
9
Clinically significant pharmacokinetic interactions between dietary caffeine and medications.饮食中的咖啡因与药物之间具有临床意义的药代动力学相互作用。
Clin Pharmacokinet. 2000 Aug;39(2):127-53. doi: 10.2165/00003088-200039020-00004.
10
Management of schizophrenia in children and adolescents. The role of clozapine.
Paediatr Drugs. 2000 Jul-Aug;2(4):253-62. doi: 10.2165/00128072-200002040-00002.
Am J Psychiatry. 1996 Dec;153(12):1579-84. doi: 10.1176/ajp.153.12.1579.
4
Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking.精神分裂症患者临床疗效与血浆中氯氮平浓度的关系:吸烟的影响。
J Clin Psychopharmacol. 1993 Dec;13(6):383-90.
5
Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome.
Am J Psychiatry. 1994 Dec;151(12):1744-52. doi: 10.1176/ajp.151.12.1744.
6
Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service.氟伏沙明对氯氮平代谢的抑制作用及卡马西平对其代谢的诱导作用:来自治疗药物监测服务的证据。
Ther Drug Monit. 1994 Aug;16(4):368-74. doi: 10.1097/00007691-199408000-00006.
7
Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects.美国和欧洲的氯氮平剂量:对治疗效果和不良反应的影响。
J Clin Psychiatry. 1994 Sep;55 Suppl B:78-81.
8
Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia.血浆氯氮平浓度可预测难治性精神分裂症的临床反应。
J Clin Psychiatry. 1994 Sep;55 Suppl B:133-6.
9
Plasma clozapine concentrations as a predictor of clinical response: a follow-up study.血浆氯氮平浓度作为临床反应预测指标的随访研究。
J Clin Psychiatry. 1994 Sep;55 Suppl B:117-21.
10
Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.难治性精神分裂症患者的血浆氯氮平水平与临床反应
Am J Psychiatry. 1995 Feb;152(2):179-82. doi: 10.1176/ajp.152.2.179.